Pfizer publishes pneumonia immunization trial results
The study determined the efficiency of the Prevenar 13 vaccine in preventing a vaccine-type pneumococcal community-acquired pneumonia (CAP) in a first episode. The study included both non-bacteremic and non-invasive CAP and vaccine-type invasive pneumococcal disease (IPD).
The study involved subjects 65 years and older.
“Since our immune system naturally weakens with age, the likelihood of getting infections increases even in otherwise healthy, active older adults, with pneumococcal community-acquired pneumonia representing a significant cause of illness in this population,” Marc Bonten, M.D., Ph.D., principal investigator and professor of molecular epidemiology of infectious diseases at the University Medical Center Utrecht in the Netherlands, said. “The results of this study demonstrated that immunization with Prevenar 13 reduced the risk of pneumococcal community-acquired pneumonia and invasive pneumococcal disease caused by the 13 serotypes in the vaccine among adults aged 65 years and older.”
The results were published in the New England Journal of Medicine.
“This landmark study was a significant achievement,” William Gruber, M.D., senior vice president of vaccine clinical research at Pfizer, said. “The study was one of the largest double-blind, randomized, placebo-controlled vaccine efficacy trials ever conducted in older adults. Its successful execution reflected the integration of clinical study design with supporting basic research-driven applications.”